ClinicalTrials.gg
Active, not recruitingNCT06292013Updated Oct 8, 2026

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

A Phase 3 interventional study of Lepodisiran Sodium and Placebo in Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Lp(a), sponsored by Eli Lilly and Company. Active, not recruiting at 928 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
17,300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Atherosclerosis by Eli Lilly and Company — 5 open to participants now, 7 under way, 4 of them phase 3. Atherosclerosis · Eli Lilly and Company.

Started
2024
with 2 others
Phase 3
4 of 10
2 open now
Registered
5th of 10
by date

Among the 10 studies in Atherosclerosis by Eli Lilly and Company, this one is one of 3 that started in 2024, is one of 4 in phase 3, and was the 5th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 225 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

5 of the 10 studies in Atherosclerosis by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 161 Atherosclerosis studies recruiting now, 84 (52%) set no upper age limit and 33 (20%) stop at 75 or younger; 16 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Atherosclerosis by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema.

03

Conditions studied

  • Atherosclerotic Cardiovascular Disease (ASCVD)
  • Elevated Lp(a)

Browse trials for

Keywords

  • ASCVD
  • LY3819469
  • lepodisiran
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Lipoprotein(a) [Lp(a)] ≥175 nanomoles per liter (nmol/L).
  • Meet criteria of either 2a or 2b:

    2a: Individuals 18 years of age or older with established atherosclerotic cardiovascular disease (ASCVD) with an event or revascularization.

    2b: Individuals 55 years of age or older who are at risk for a first cardiovascular (CV) event and either: Documented coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without history of event or revascularization; known familial hypercholesteremia; or a combination of high-risk factors.

Exclusion criteria

Exclusion Criteria:

  • Have had a major cardiovascular event or surgery, such as myocardial infarction (MI), stroke or coronary or peripheral revascularization, \< 60 days before screening
  • Have uncontrolled hypertension
  • Have class IV heart failure.
  • Have lipoprotein apheresis within 90 days of screening, or planned lipoprotein apheresis during the study.
  • Have severe renal failure, defined as

    • Estimated glomerular rate () \<15 milliliters per minute per 1.73 meters squared (mL/min/1.73m2) at screening Visit 1, or ongoing dialysis.
  • Have a diagnosis of active nephrotic syndrome, or urine albumin-creatinine ratio (UACR) of ≥5000 mg/g at screening Visit 1.
  • Have acute or chronic hepatitis, known cirrhosis, signs and symptoms of any other liver disease other than metabolic-associated steatotic liver disease, or exclusionary laboratory results as determined by the central laboratory during screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
17,300 participants (estimated)

Study arms

  • Experimental
    Lepodisiran Sodium

    Lepodisiran sodium administered subcutaneously (SC).

    Drug: Lepodisiran Sodium

  • Placebo comparator
    Placebo

    Placebo administered SC.

    Drug: Placebo

Interventions

  • DrugLepodisiran Sodium

    Administered SC

    Also known as: LY3819469

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint

    Time to first event in a MACE-4 composite endpoint, comprised of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent coronary revascularization.

    Time frame: Baseline up to End of Study (About 4.5 Years)

Secondary outcomes

  1. Change from Baseline in Lipoprotein(a) [Lp(a)] at Week 4

    Change from Baseline in Lp(a)

    Time frame: Baseline, Week 4

  2. Time to First Occurrence of Any of the Component of MACE-3 Composite Endpoint

    Time to first occurrence MACE-3

    Time frame: Baseline up to End of Study (About 4.5 Years)

  3. Time to First Occurrence of Fatal or Non-Fatal Myocardial Infarction

    Time to first occurrence of fatal or non-fatal myocardial infarction.

    Time frame: Baseline up to End of Study (About 4.5 Years)

  4. Time to Cardiovascular Death

    Time to cardiovascular death.

    Time frame: Baseline up to End of Study (About 4.5 Years)

  5. Time to Occurrence of All-Cause Death

    Time to occurrence of all-cause death

    Time frame: Baseline up to End of Study (About 4.5 Years)

  6. Time to First Occurrence of Any Component of the MACE-4 Composite Endpoint (In the Population with Established ASCVD and CV Event, or Revascularization)

    Time to first occurrence of any component of the MACE-4 composite endpoint.

    Time frame: Baseline up to End of Study (About 4.5 Years)

  7. Time to First Occurrence of any Component of the MACE-4 Composite Endpoint (In the Population At Risk for First CV event)

    Time to first occurrence of any component of the MACE-4 composite endpoint.

    Time frame: Baseline up to End of Study (About 4.5 Years)

  8. Time to First Occurrence of any Component of the MACE-4 Composite Endpoint (In the Population with Lp(a) ≥ 200 nmol/L)

    Time to first occurrence of any component of the MACE-4 composite endpoint.

    Time frame: Baseline up to End of Study (About 4.5 Years)

  9. Time to First Occurrence of Any Component of MACE-3 + MALE Composite Endpoint

    Time to first occurrence of any component of MACE-3 + MALE composite endpoint.

    Time frame: Baseline up to End of Study (About 4.5 Years)

  10. Time to First Occurrence of Any Component of Coronary MACE-3 Composite Endpoint

    Time to first Occurrence of any component of coronary MACE-3 composite endpoint.

    Time frame: Baseline up to End of Study (About 4.5 Years)

07

Study locations

928 sites

Showing the first 100 of 928 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Byambaa E, Roshanravan B, Berglund L. Lipoprotein(a) and CKD: Insights into New Therapeutic Opportunities. Clin J Am Soc Nephrol. 2026 Aug 1;21(8):1469-1481. doi: 10.2215/CJN.0000000968. Epub 2025 Dec 2. PubMed 41329869 ↗
  • Nicholls SJ. Therapeutic lowering of lipoprotein(a): implications for improving outcomes in patients with peripheral arterial disease. Curr Opin Lipidol. 2025 Oct 1;36(5):232-237. doi: 10.1097/MOL.0000000000001002. Epub 2025 Jul 21. PubMed 40699211 ↗
  • Nicholls SJ, Nelson AJ, Michael LF. Oral agents for lowering lipoprotein(a). Curr Opin Lipidol. 2024 Dec 1;35(6):275-280. doi: 10.1097/MOL.0000000000000953. Epub 2024 Sep 25. PubMed 39329200 ↗

Related links

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2029, 60 months after the start.

Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's planned 60 months is above that.

Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Mar 4, 2024
StartActual
Mar 5, 2024
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06292013
Responsible party
Sponsor
First posted
Mar 4, 2024
Start date
Mar 5, 2024
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Oct 8, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion